Edwin A. Basak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Edwin A. Basak has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Astrid A.M. van der Veldt
Dept. of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Dept. of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands
3 shared publicationsJoachim G.J.V. Aerts
Dept. of Pulmonology, Erasmus University Medical Center, Rotterdam, the Netherlands
3 shared publicationsMarco W.J. Schreurs
Dept. of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands
3 shared publications- Sander Bins
Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands
3 shared publications Arjen Joosse
Dept. of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
2 shared publications- Daan Hurkmans
Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 11 October 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 156, 113839
The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy
- 11 October 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 156, 113839
Open AccessThe course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy
- Open Access
- 18 August 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 174, 113-120
Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study
- 18 August 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 174, 113-120
Open AccessAssociations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study
- Open Access
- 19 July 2019
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 7 (1) , 192
A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
Background Nivolumab is administered in a weight-based or fixed-flat dosing regimen. For patients with non-small cell lung cancer (NSCLC), a potential exposure-response relationship has recently been reported and may argue against the current dosing strategies. The primary objectives were to determine nivolumab pharmacokinetics (PK) and to assess the relationship between drug clearance and clinical outcome in NSCLC, melanoma, and renal cell cancer (RCC). Methods In this prospective observational cohort study, individual estimates of nivolumab clearance and the impact of baseline covariates were determined using a population-PK model. Clearance was related to best overall response (RECISTv1.1), and stratified by tumor type. Results Two-hundred-twenty-one patients with metastatic cancer receiving nivolumab-monotherapy were included of whom 1,715 plasma samples were analyzed. Three baseline parameters had a significant effect on drug clearance and were internally validated in the population-PK model: gender, BSA, and serum albumin. Women had 22% lower clearance compared to men, while the threshold of BSA and albumin that led to > 20% increase of clearance was > 2.2m2 and < 37.5 g/L, respectively. For NSCLC, drug clearance was 42% higher in patients with progressive disease (mean: 0.24; 95% CI: 0.22–0.27 L/day) compared to patients with partial/complete response (mean: 0.17; 95% CI: 0.15–0.19 L/day). A similar trend was observed in RCC, however, no clearance-response relationship was observed in melanoma. Conclusions Based on the first real-world population-PK model of nivolumab, covariate analysis revealed a significant effect of gender, BSA, and albumin on nivolumab clearance. A clearance-response relationship was observed in NSCLC, with a non-significant trend in RCC, but not in melanoma. Individual pharmacology of nivolumab in NSCLC appears important and should be prospectively studied.
- 19 July 2019
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 7 (1) , 192
Open AccessA prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
Background Nivolumab is administered in a weight-based or fixed-flat dosing regimen. For patients with non-small cell lung cancer (NSCLC), a potential exposure-response relationship has recently been reported and may argue against the current dosing strategies. The primary objectives were to determine nivolumab pharmacokinetics (PK) and to assess the relationship between drug clearance and clinical outcome in NSCLC, melanoma, and renal cell cancer (RCC). Methods In this prospective observational cohort study, individual estimates of nivolumab clearance and the impact of baseline covariates were determined using a population-PK model. Clearance was related to best overall response (RECISTv1.1), and stratified by tumor type. Results Two-hundred-twenty-one patients with metastatic cancer receiving nivolumab-monotherapy were included of whom 1,715 plasma samples were analyzed. Three baseline parameters had a significant effect on drug clearance and were internally validated in the population-PK model: gender, BSA, and serum albumin. Women had 22% lower clearance compared to men, while the threshold of BSA and albumin that led to > 20% increase of clearance was > 2.2m2 and < 37.5 g/L, respectively. For NSCLC, drug clearance was 42% higher in patients with progressive disease (mean: 0.24; 95% CI: 0.22–0.27 L/day) compared to patients with partial/complete response (mean: 0.17; 95% CI: 0.15–0.19 L/day). A similar trend was observed in RCC, however, no clearance-response relationship was observed in melanoma. Conclusions Based on the first real-world population-PK model of nivolumab, covariate analysis revealed a significant effect of gender, BSA, and albumin on nivolumab clearance. A clearance-response relationship was observed in NSCLC, with a non-significant trend in RCC, but not in melanoma. Individual pharmacology of nivolumab in NSCLC appears important and should be prospectively studied.
- 1 March 2019
- Published by Elsevier in European Journal of Cancer
- Vol. 109, 12-20
Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer
- 1 March 2019
- Published by Elsevier in European Journal of Cancer
- Vol. 109, 12-20
Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer